| Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia. | |
| | |
MedLine Citation:
|
PMID: 19887962 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The syndrome of hyperammonemic encephalopathy occurs in patients who have received high-dose cytoreductive therapy for the treatment of hematologic malignancy. It is characterized by acute alteration in mental status and respiratory alkalosis associated with markedly elevated plasma ammonium levels in the absence of any identifiable cause and frequently results in cerebral edema, coma, and eventually death. Although the etiology of this syndrome is yet to be determined, it seems to be invariably multifactorial in nature. Optimal therapy remains elusive, and the critical step is increased awareness of the syndrome by measurement of plasma ammonia levels in patients with neurologic symptoms, leading to accurate diagnosis and the rapid implementation of therapy. |
| | |
Authors:
|
Tang-Her Jaing; Ju-Li Lin; Yu-Pi Lin; Shu-Ho Yang; Jiann-Jim Lin; Shao-Hsuan Hsia |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Journal of pediatric hematology/oncology Volume: 31 ISSN: 1536-3678 ISO Abbreviation: J. Pediatr. Hematol. Oncol. Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-12-03 Completed Date: 2010-01-07 Revised Date: 2011-10-06 |
Medline Journal Info:
|
Nlm Unique ID: 9505928 Medline TA: J Pediatr Hematol Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 955-6 Citation Subset: IM |
Affiliation:
|
Division of Hematology and Oncology, Department of Pediatrics, Chang Gung Children's Hospital, Chang Gung University, Taoyuan, Taiwan. jaing001@cgmh.org.tw |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Combined Chemotherapy Protocols
/
adverse effects* Asparaginase / adverse effects Daunorubicin / adverse effects Humans Hyperammonemia / chemically induced*, therapy Infant Male Neurotoxicity Syndromes / etiology*, therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy* Prednisone / adverse effects Remission Induction Treatment Outcome Vincristine / adverse effects |
| Chemical | |
Reg. No./Substance:
|
20830-81-3/Daunorubicin; 53-03-2/Prednisone; 57-22-7/Vincristine; EC 3.5.1.1/Asparaginase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Acquired tracheoesophageal fistula during treatment for pediatric acute lymphoblastic leukemia.
Next Document: Medulloblastoma incidence has not changed over time: a CBTRUS study.